Welcome to our dedicated page for Cormedix SEC filings (Ticker: CRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CorMedix Inc. (CRMD) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, offering a detailed view of its financial condition, governance, and material events. CorMedix is a Nasdaq Global Market–listed biopharmaceutical company focused on therapeutic products for life-threatening conditions and diseases, including DefenCath for catheter-related bloodstream infection prevention and a portfolio of anti-infective and hospital products acquired through Melinta Therapeutics LLC.
Current reports on Form 8-K document significant developments such as the completion of the Melinta acquisition, the related contingent payment and registration rights agreements, the issuance of convertible senior notes, equity offerings, and preliminary or final quarterly results. For example, a Form 8-K filed on November 12, 2025 furnishes third-quarter 2025 financial results and guidance updates, while earlier 8-Ks describe the Melinta transaction terms and the convertible notes offering used in part to fund the deal.
Proxy statements on Schedule 14A provide insight into CorMedix’s corporate governance and capital structure decisions. A definitive proxy statement filed in October 2025 outlines proposals for a special meeting, including amendments to the company’s stock incentive plan, ratification of certificate of designation amendments, and changes to its certificate of incorporation affecting preferred stock voting rights.
Investors can also use this page to access periodic reports referenced in the company’s proxy and 8-K filings, which contain audited financial statements, risk factors, and management’s discussion and analysis. These filings explain how CorMedix reports revenue from DefenCath and the Melinta portfolio, records goodwill and intangible assets, and accounts for items such as deferred tax assets and non-GAAP measures like adjusted EBITDA.
In addition, insider and capital markets–related filings are available, including disclosures about equity offerings, convertible notes, and voting results from annual and special meetings. Stock Titan’s interface pairs these documents with AI-powered summaries that highlight key points from lengthy 10-K, 10-Q, 8-K, and proxy materials, helping users quickly understand transaction terms, clinical program disclosures, and changes in guidance without reading every page.
CorMedix Inc. filed Amendment No. 1 to a prior current report to provide additional financial information related to its completed acquisition of Melinta Therapeutics, LLC. The amendment relates to the merger that closed on August 29, 2025 under the Agreement and Plan of Merger dated August 7, 2025.
The filing adds audited consolidated financial statements of Melinta for the years ended December 31, 2024 and 2023, unaudited condensed consolidated financial statements for the six months ended June 30, 2025, and unaudited pro forma condensed combined financial information for the year ended December 31, 2024 and the six months ended June 30, 2025. These materials are included as Exhibits 99.2, 99.3 and 99.4, along with an auditor consent.
CorMedix Inc. director Gregory Scott Duncan reported insider transactions on 09/16/2025. The filing shows an acquisition of 13,333 shares of common stock at $8.32 per share, bringing his total common stock beneficially owned to 38,333 shares. The report also lists a derivative transaction showing 13,333 stock options with an $8.32 exercise price, exercisable beginning 01/10/2031, and 6,667 derivative shares beneficially owned following the transaction. The form notes these options were granted 01/11/2021 and vest monthly with full vesting after one year, subject to continued board service.
Alan W. Dunton, a director of CorMedix Inc. (CRMD), reported same-day transactions on 09/12/2025 in the company's common stock and related options. He exercised a stock option with a $3.55 exercise price to acquire 10,000 shares, increasing his direct holdings to 50,250 shares, and sold 10,000 shares the same day in multiple trades at a weighted average price of $13.13, reducing his direct holdings to 40,250 shares. The Form 4 discloses the option grant date of 03/05/2024 and that those options vest monthly with full vesting one year after grant. The filing is signed and dated 09/16/2025.
CorMedix Inc. is soliciting votes at a virtual special meeting to approve three proposals: removal of an exchange cap, an amendment to its 2022 Stock Incentive Plan to increase authorized shares from 8,160,000 to 12,472,000, and an adjournment proposal. The amendment would make the additional shares available for a variety of equity awards including incentive stock options, SARs, restricted stock and RSUs to attract and retain employees, consultants and directors. The proxy discloses potential contingent consideration tied to a prior transaction including up to $25,000,000 in milestone payments payable in cash, stock or warrants and references Merger Warrants and Notes. The company reported the Nasdaq closing price of its common stock as $12.75 on September 8, 2025. The materials explain voting mechanics, broker non-vote treatment, beneficial ownership disclosure for certain holders and deadlines for 2026 stockholder proposals.
CorMedix Inc. insider Beth Zelnick Kaufman reported multiple transactions on 09/09/2025. She acquired 50,000 shares by exercising options at an exercise price of $3.30 (options originally granted 12/12/2023, vesting over four years). On the same date she disposed of 49,600 shares at a weighted average price of $13.41 and 400 shares at $12.82. Following these trades her beneficial ownership is reported as 180,418 shares.
Elizabeth Hurlburt, Chief Operating Officer of CorMedix Inc. (CRMD), reported option exercises and subsequent open-market sales in September 2025. On 09/09/2025 she exercised 12,876 stock options at an exercise price of $1.45 and sold 12,876 shares at a weighted average price of $13.51. On 09/11/2025 she exercised 41,121 options at $1.45 and sold 41,121 shares at a weighted average price of $13.08. Following these transactions her beneficial ownership is reported as 176,990 shares. The exercised options were originally granted 03/19/2018 with scheduled vesting and milestone-based vesting for remaining amounts.
CorMedix Inc. (CRMD) submitted a Form 144 notice reporting a proposed sale of 50,000 common shares through Merrill Lynch on NASDAQ with an approximate aggregate market value of $673,000. The filing lists total shares outstanding as 74,648,992 and shows the securities were acquired under Stock Plan Activity on 09/09/2025, with the intended sale date also 09/09/2025. The filer indicates there were no securities sold in the past three months by the reporting person. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
CorMedix Inc. filed a Form 144 reporting a proposed sale of 53,997 common shares through Merrill Lynch on 09/09/2025. The filing lists an aggregate market value of $728,959.00 and indicates 74,648,992 shares outstanding for the issuer. The shares were acquired the same day (09/09/2025) under a stock plan activity from the issuer, with payment recorded as n/a. No securities were reported sold by the filer in the prior three months. The notice includes the standard statement that the seller does not possess undisclosed material adverse information and warns that false statements are criminally punishable.
CorMedix insider amendment reports a tax-withholding share disposition by Elizabeth Hurlburt, the company's Chief Operating Officer and a director. The filing shows 8,424 shares of common stock were withheld by the issuer at an effective price of $14.83 to satisfy the reporting person's tax liability, reducing her direct beneficial ownership to 176,990 shares. The Form 4/A amends an earlier filing to disclose this withheld amount. The disclosure is a mechanical equity withholding for taxes rather than an open-market sale and does not report derivative transactions.
Beth Zelnick Kaufman, Chief Legal Officer and Director of CorMedix Inc. (CRMD), reported a non-derivative disposition of 8,880 shares of common stock executed on 08/29/2025 at a price of $14.83 per share. The transaction reflects the issuer withholding 8,880 shares to satisfy the reporting person's tax withholding obligation, which was omitted from an earlier filing and is corrected here. After the withheld shares, the reporting person beneficially owns 180,418 shares. The amendment clarifies the nature of the disposition and updates the ownership total.